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Abstract
Background: CD8+ T-lymphocytes, natural killer T-like cells (NKT-like cells, CD56+CD3+) and natural killer cells (NK cells,
CD56+CD32) are the three main classes of human killer cells and they are implicated in the pathogenesis of chronic
obstructive pulmonary disease (COPD). Activation of these cells can initiate immune responses by virtue of their production
of inflammatory cytokines and chemokines that cause lung tissue damage, mucus hypersecretion and emphysema. The
objective of the current study was to investigate the activation levels of human killer cells in healthy non-smokers, healthy
smokers, ex-smokers with COPD and current smokers with COPD, in both peripheral blood and induced sputum.
Methods/Principal Findings: After informed consent, 124 participants were recruited into the study and peripheral blood or
induced sputum was taken. The activation states and receptor expression of killer cells were measured by flow cytometry. In
peripheral blood, current smokers, regardless of disease state, have the highest proportion of activated CD8+ T-
lymphocytes, NKT-like cells and NK cells compared with ex-smokers with COPD and healthy non-smokers. Furthermore,
CD8+ T-lymphocyte and NK cell activation is positively correlated with the number of cigarettes currently smoked.
Conversely, in induced sputum, the proportion of activated killer cells was related to disease state rather than current
smoking status, with current and ex-smokers with COPD having significantly higher rates of activation than healthy smokers
and healthy non-smokers.
Conclusions: A differential effect in systemic and lung activation of killer cells in COPD is evident. Systemic activation
appears to be related to current smoking whereas lung activation is related to the presence or absence of COPD,
irrespective of current smoking status. These findings suggest that modulating killer cell activation may be a new target for
the treatment of COPD.
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Introduction
COPD is defined as a chronic inflammatory lung disease
leading to irreversible airflow limitation as confirmed by spirom-
etry [1]. Chronic bronchiolitis, emphysema and mucus hyperse-
cretion are three main pathological features of COPD [2,3], which
result in the common and characteristic symptoms, including
chronic cough and progressive dyspnoea [4]. COPD is predicted
to be the third major worldwide cause of death by 2020 [5].
CD8+ T-lymphocytes, NKT-like cells and NK cells are the
three main types of killer cells in the immune system and have
been implicated in the pathogenesis of COPD [6,7,8,9,10,11,12].
Previous studies have shown that increased numbers of CD8+ T-
lymphocytes are found in both the peripheral airways and lower
respiratory tract in patients with COPD [13,14]. We have
previously shown that the numbers and cytotoxicity of NK and
NKT-like cells are increased in induced sputum of patients with
COPD [9] but are reduced in the peripheral blood [11], implying
a potential role in disease pathogenesis.
For killer cells to be functional they need to be activated. CD69
and CD25 are cell surface markers of early and late stages of
lymphocyte activation, respectively [15]. This activation involves
several factors, such as interaction between antigen receptors and
peptides presented by MHC class I molecules or MHC class I-
related proteins. Human killer cells express immunoglobulin-like
receptors (KIRs), belonging to the Ig superfamily (CD158 family),
which bind to MHC Class I. They can be classified into two
groups, namely, inhibitory KIRs and activating KIRs. Inhibitory
KIRs possess long (L) cytoplasmic domains, such as KIR2DL or
KIR3DL. Activating KIRs possess short cytoplasmic domains with
an immunoreceptor tyrosine-based activation motif (ITAM)-
bearing DAP12 adapter protein [16]. NKG2D is a unique
activating receptor and a type II transmembrane-anchored
glycoprotein. It transmits signals through its transmembrane
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segment associating with adaptor protein DAP10 and in the
absence of DAP10, NKG2D is not able to be presented on the cell
surface and is retained in the cytoplasm [17,18]. Its expression can
be regulated by cytokines; for example, IL-15 and TNF-a can
enhance NKG2D expression whereas TGF-b causes its down-
regulation [19,20,21]. In humans, KIR3DL1 (CD158e1) and
NKG2D are two representative signalling receptors expressed by
CD8+ T-lymphocytes, NK cells, NKT cells and cd TCR+ T cells
[18,22,23,24,25]. They can recognise MHC class I molecules and
MHC class I-related proteins, respectively.
Several studies have investigated expression of activation
markers on T-lymphocytes from peripheral blood, induced
sputum and bronchial alveolar lavage (BAL) fluid from healthy
smokers and COPD patients with varying results [26,27,28] but
none have looked specifically at CD8 T lymphocytes, NKT-like
and NK cells.
In this study, we investigated the activation levels (by
measurement of CD69 and CD25 expression) of the three main
classes of human killer cells, namely, CD8+ T-lymphocytes, NKT-
like cells and NK cells, in peripheral blood and induced sputum.
Samples were obtained from four groups of participants including
Table 1. Demographic and spirometric values of groups examined for the activation studies in the peripheral blood.
Healthy
non-smokers Healthy smokers exS-COPD cuS-COPD
Participants 21 21 10 14
Age (years) 53 (42–68) 55 (43–68) 63 (49–75) 62 (45–77)
Gender (M/F) 14/7 10/11 5/5 7/7
Packs/yrs 0 43 (15–68) 45 (20–71) 53 (23–77)
Smoking status (Current/Ex) 0 21/0 0/10 14/0
Chronic bronchitis
(Yes/No)
0 7/14 8/2 8/6
FEV1 (% pred) 107 (75–140) 102 (85–128) 50 (18–66) 41 (17–61)
FEV1/FVC (%) 90 (67–127) 80 (66–107) 51 (36–65) 46 (29–66)
nFEV1 post bronch 2.4 (1.9–3.4) 2.7 (1.7–3.8) 1.4 (0.6–2.0) 1.9 (0.5–2.9)
BMI (kg/m2) 24.6 (17.8–32.2) 25.5 (19.2–36.9) 22.5 (20.6–24.7) 26.2 (18.3–35.6)
Inhaled GCS (on/off) N/A N/A 5/5 6/8
MRC dyspnoea scale N/A N/A 2 (1–4) 3 (2–4)
Distance walked in 6 min (m) N/A N/A 313 (140–492) 314 (50–431)
BODE Index N/A N/A 4 (1–5) 5 (2–7)
Results are expressed as median with range in brackets.
doi:10.1371/journal.pone.0058556.t001
Table 2. Demographic and spirometric values of groups examined for the KIR studies in the peripheral blood.
Healthy
non-smokers Healthy smokers exS-COPD cuS-COPD
Participants 8 8 7 9
Age (years) 54 (47–66) 53 (45–63) 62 (49–69) 61 (45–77)
Gender (M/F) 4/4 3/5 3/4 3/6
Packs/yrs 0 35 (32–40) 36 (20–51) 56 (30–77)
Smoking status (Current/Ex) 0 8/0 0/7 9/0
Chronic bronchitis
(Yes/No)
0 3/5 5/2 6/3
FEV1 (% pred) 105 (75–126) 101 (85–114) 58 (52–66) 41 (30–61)
FEV1/FVC (%) 104 (67–120) 89 (66–101) 51 (36–65) 48 (29–53)
nFEV1 post bronch 2.2 (1.9–3.0) 2.1 (1.7–2.9) 1.1 (0.6–1.5) 1.6 (1.1–2.4)
BMI (kg/m2) 22.8 (18.7–26.2) 24.7 (19.2–31.6) 21.5 (19.6–23.1) 23.2 (18.3–30.8)
Inhaled GCS (on/off) N/A N/A 4/3 3/6
MRC dyspnoea scale N/A N/A 2 (1–4) 3 (2–4)
Distance walked in 6 min (m) N/A N/A 277 (140–456) 308 (50–431)
BODE Index N/A N/A 5 (1–6) 5 (2–7)
Results are expressed as median with range in brackets.
doi:10.1371/journal.pone.0058556.t002
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healthy non-smoking volunteers, healthy smokers, ex-smokers with
COPD and current smokers with COPD. To further detect the
association between cell activation and their functional receptors
in peripheral blood samples, we also examined the expression of
the inhibitory receptor KIR3DL1 (CD158e1) and the activating
receptor NKG2D in these four groups.
Materials and Methods
Study population and procedures
The Nottingham Research Ethics Committee approved the
study protocol (REC reference 04/Q2403/102) and written
informed consent was obtained from all participants before
entering the study. Sixty-six participants were included in the
peripheral blood activation study, thirty-two in the KIR study and
twenty-six in the induced sputum study. Participants were
diagnosed as having COPD according to the ATS guidelines;
they were either current smokers with COPD or ex-smokers with
COPD and had accrued at least a 20 pack year smoking history.
Healthy smokers and healthy non-smokers, with an FEV1 above
80% of predicted, were matched, as far as possible, for age, with
participants with COPD; healthy smokers were also matched for
smoking history. Table 1 details the demographic and spirometric
data of the participants in the activation study; table 2 the KIR
study and table 3 the induced sputum study. Participants were
excluded as previously stated [29,30]; specifically, they were all
non-atopic (negative skin prick test response to common allergen
extracts including grass pollen, house dust mite, cat dander and
dog hair) and all COPD patients had been free of an acute
exacerbation of COPD for at least 6 weeks preceding the study. In
addition, none had received antibiotics or corticosteroids (oral and
inhaled) over the same period.
Table 3. Demographic and spirometric values of the induced sputum studied groups.
Healthy non-smokers Healthy smokers exS-COPD cuS-COPD
Participants 5 10 6 5
Age (years) 51 (42–68) 51 (44–68) 62 (44–69) 69 (61–73)
Gender (M/F) 1/4 5/5 4/2 2/3
Packs/yrs 0 (0) 35 (19–51) 49 (27–77) 51 (41–62)
Smoking status (Current/Ex) 0 10/0 0/6 5/0
Chronic bronchitis
(Yes/No)
0 4/6 3/3 4/1
FEV1 (% pred) 112 (88–124) 100 (89–122) 59 (37–73) 59 (45–68)
FEV1/FVC (%) 78 (72–86) 74 (73–82) 55 (39–69) 45 (39–59)
nFEV1 post bronch 2.2 (1.1–3.5) 1.6 (1.1–2.7) 3.8 (3.6–4.1) 3.9 (3.6–4.3)
BMI (kg/m2) 26.4 (18.9–29.3) 23.8 (20.0–31.0) 27.2 (20.2–34.0) 23.5 (19.3–25.7)
Inhaled GCS (on/off) N/A N/A 4/2 3/2
MRC dyspnoea scale N/A N/A 3 (2–4) 3 (2–4)
Distance walked in 6 min (m) N/A N/A 359 (168–554) 288 (225–390)
BODE Index N/A N/A 4 (1–7) 5 (2–6)
Results are expressed as median with range in brackets.
doi:10.1371/journal.pone.0058556.t003
Table 4. Antibodies used for flow cytometry.
Antigen Fluorochrome Isotype Clone Source
CD3 ECD
PC7
Mouse IgG1 UCHT1 Beckman Coulter, Luton, UK
CD8 PC5
APC
Mouse IgG1 B9.11 Beckman Coulter, Luton, UK
CD8 ECD Mouse IgG1 SFCl21Thy2D3 Beckman Coulter, Luton, UK
CD25 FITC
PE




Mouse IgG1 N901 Beckman Coulter, Luton, UK
CD69 ECD
PC5
Mouse IgG2b TP1.55.3 Beckman Coulter, Luton, UK
KIR3DL1
(CD158e1)
FITC Mouse IgG1, k DX9 Biolegend, San Diego, CA, USA
NKG2D (CD314) PE Mouse IgG1 ON72 Beckman Coulter, Luton, UK
doi:10.1371/journal.pone.0058556.t004
Killer Cell Activation States Ex Vivo in COPD
PLOS ONE | www.plosone.org 3 March 2013 | Volume 8 | Issue 3 | e58556
Peripheral Blood Mononuclear Cell isolation
Peripheral blood mononuclear cells (PBMCs) were isolated from
whole blood on a discontinuous histopaque density gradient
(Sigma, Poole, UK). Briefly, 50 ml of whole blood were diluted 2:1
in RPMI 1640 medium (Sigma, Poole, UK), layered over
histopaque and centrifuged for 22 minutes at 800 g. The resultant
mononuclear layer was removed and washed twice and resus-
pended.
Sputum induction and cell isolation
Sputum was induced by inhalation of hypertonic saline as
described previously [31] with the difference that the participant
was given salbutamol (400 mg) via a volumatic, rather than 1 mg
terbutaline. The sample was placed on ice and processed within
1 hour. The cells were isolated as previously described [30].
Briefly, sputum was mixed with an equal volume of PBS (Sigma,
Poole, UK), then filtered through 48 mm nylon gauze (Sefar, Bury,
UK). An aliquot was taken for cell counting to assess viability and
squamous cell contamination, and the remaining sample was
resuspended for use in flow cytometry.
Flow cytometric analysis
Cells were stained for flow cytometry as previously described
[29]. Briefly, cells were fixed in 3% formaldehyde in isotonic azide
free solution (Beckman Coulter, Luton, UK) and washed before
labelled antibodies (Table 4) were added at the recommended
concentration. The cells were incubated in the dark and excess
antibody removed. Flow cytometric analysis of antibody labelled
cells was performed using an EPICS Altra (Beckman Coulter,
Luton, UK). Fifty thousand live-gated events were collected for
each sample and isotype matched antibodies were used to
determine binding specificity. Data were analysed using WEASEL
version 2.3 (WEHI). Necrotic cells were excluded from analysis
according to their forward and side scatter characteristics.
Statistical analysis
The statistical analysis was performed with Prism software,
version 4.0c (GraphPad). Normality was detected using the
Kolmogorov–Smirnov test. As some data were non-normally
distributed all are expressed as median and range, unless otherwise
stated. Differences between the three groups of participants were
tested using the non-parametric Kruskal-Wallis test with post hoc
pairwise comparisons made by the Dunn’s Multiple Comparison
test to determine which pair was statistically significantly different.
P values #0.05 were considered to indicate statistical significance.
Results
Demographic and Medical Characteristics of COPD
participants, Healthy Smokers and Healthy Controls
There were no statistical differences between groups in terms of
age or pack years smoked between ex-smokers with COPD, current
Figure 1. Representative dot plots gating for live/dead cells, identification of cell populations and expression of activation markers
by CD8+ T lymphocytes from four groups. (i)(A) Forward Scatter (FS) vs Side Scatter (SS) plot for identification of live and dead cells; (B)
Identification of CD8+ T lymphocytes (CD3+CD8+); and (C) identification of NK cells (CD3-CD56+) and NKT-like cells (CD3+CD56+). (ii) Representative
dot plots for activation of CD8+ T lymphocytes expressing either CD69 alone (lower right quadrant), CD69 and CD25 (upper right quadrant) or CD25
alone (upper left quadrant) in four groups: (A) Healthy non-smoking participant; (B) Healthy smoker; (C) Current smoker with COPD; and (D) ex-
smoker with COPD.
doi:10.1371/journal.pone.0058556.g001
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smokers with COPD and healthy smokers. Furthermore, there was
no statistical difference in the inhaled corticosteroid use between ex-
smokers with COPD and current smokers with COPD.
Killer cell activation in peripheral blood
All individuals had similar total mononuclear cell numbers,
which were within the normal range. Representative flow analysis
dot plots of Forward Scatter (FS) vs Side Scatter (SS) for
identification of live and dead cells, together with dot plots for
identification of CD8+ T-lymphocytes (CD3+CD8+); NK cells
(CD3-CD56+) and NKT-like cells (CD3+CD56+), along with dot
plots for CD69 and CD25 staining of peripheral blood CD8+ T-
lymphocytes, are shown in Figure 1. Cells are designated activated
when they express one or both of the activation markers (i.e.,
CD69 positive, CD69/CD25 double positive or CD25 positive).
Significantly more CD8+ T-lymphocytes from both healthy
smokers (52.3%, 27.2–72.8; p,0.001) and current smokers with
Figure 2. Activation of killer cells from peripheral blood ex vivo
of four groups. Activation of CD8+ T-lymphocytes, NKT-like cells and
NK cells was analysed. There was a significant increase in level of
activation ex vivo of CD8+ T lymphocytes (panel A), NKT-like
(CD56+CD3+) cells (panel B) and NK (CD56+CD32) cells (panel C) from
both healthy smokers (HS, open circles) and cuS-COPD (solid circles).
Activation of NK (CD56+CD32) cells from exS-COPD (grey solid circles)
was also significantly increased compared with healthy non-smokers
(HNS). *: p,0.05, **: p,0.01, ***: p,0.001. HNS (n = 21), HS (n = 21),
cuS-COPD participants (n = 14) and exS-COPD (n= 10).
doi:10.1371/journal.pone.0058556.g002
Figure 3. Correlation of the proportion of cells activated and
number of cigarettes currently smoked per day. Analysis was
performed on peripheral blood CD8+ T lymphocytes (Panel A), NKT-like
(CD56+CD3+) cells (Panel B) and NK (CD56+CD32) cells (Panel C). A
significant correlation was observed in CD8+ T lymphocytes and NK
(CD56+CD32) cells but not NKT-like (CD56+CD3+) cells.
doi:10.1371/journal.pone.0058556.g003
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COPD (34.3%, 13.8–56.2; p,0.001) were activated ex vivo
compared to healthy non-smokers (5.1%, 2.5–13.3) (Figure 2A).
However, there were no significant differences in the activation of
CD8+ T-lymphocytes between ex-smokers (24.1%, 4.7–48.4) and
healthy smokers (52.3%, 27.2–72.8; p.0.05) or current smokers
with COPD (34.3%, 13.8–56.2; p.0.05). Analyses of individual
markers (i.e., CD69 positive/CD25 negative; CD69 negative/
CD25 positive; OR CD69 positive/CD25 positive) were not
different between groups or cell types (data not shown).
NKT-like cells showed a similar pattern to CD8+ T-lympho-
cytes, namely significantly more ex vivo activation from both
healthy smokers (46.0%, 17.7–58.7; p,0.001) and current
smokers with COPD (33.0%, 15.4–65.3; p,0.001) compared to
healthy non-smokers (7.8%, 4.3–16.9) (Figure 2B). Also, no
significant differences in NKT-like cell activation were observed
between ex-smokers (24.3%, 12.4–48.1) and healthy non-smoker
(7.8%, 4.3–16.9; p.0.05) or current smokers with COPD (33.0%,
15.4–65.3; p.0.05).
NK (CD56+CD32) cells from healthy smokers (25.6%, 14.1–
50.1; p,0.001), current smokers with COPD (35.1%, 13.2–72.8;
p,0.001) and ex-smokers with COPD (18.4%, 11.9–58.8;
p,0.005) were significantly more activated ex vivo than those
from healthy non-smokers (8.9%, 3.6–22.8) (Figure 2C).
In view of our findings of the effect of current smoking we
looked for correlations between the number of cigarettes currently
being smoked per day and level of ex vivo cell activation for the
three cell types (Figure 3). CD8+ T-lymphocytes and NK cells
showed a significant positive correlation between the proportion of
ex vivo activation and number of cigarettes smoked (r = 0.5617,
p = 0.0004; r = 0.3853, p = 0.0223, respectively) (Figures 3A and
3C). No such correlation was observed for NKT-like cells
(r = 0.08851, p = 0.6131) (Figure 3B).
CD158e1 and NKG2D expression in peripheral blood
To examine a possible effect of cell activation on the function of
killer cells, expression of the inhibitory KIR CD158e1 was
measured by flow cytometry (Figure 4). Representative dot plots of
KIR expression from healthy non-smokers (Panel A); healthy
smokers (Panel B); current smokers with COPD (Panel C) and ex-
smokers with COPD (Panel D) are shown in Figure 4i.
A significantly lower proportion of CD8+ T-lymphocytes from
healthy smokers (0.8%, 0.1–2.2; p,0.001) and current smokers
with COPD (0.7%, 0.1–3.9; p,0.001) expressed CD158e1 on the
cell surface compared to healthy non-smokers (9.9%, 4.8–16.6)
(Figure 4iiA).
The proportion of NKT-like cells expressing surface CD158e1
was also significantly lower in healthy smokers (2.1%, 0.2–7.9;
p,0.001) and current smokers with COPD (2.2%, 1.6–6.8;
p,0.001) compared to healthy non-smokers (13.3%, 9.0–20.2)
(Figure 4iiB).
Analysis of NK cells showed the proportion of these cells
expressing surface CD158e1 was also significantly lower in healthy
smokers (7.7%, 3.1–13.2; p,0.01) and current smokers with
COPD (4.8%, 2.1–16.3; p,0.001) compared to healthy non-
smokers (24.2%, 18.1–29.3) (Figure 4iiC).
No differences in proportions of CD8+ T-lymphocytes, NKT-
like cells or NK cells (in all cases over 95%) expressing NKG2D
were shown between the four groups (data not shown).
Killer cell activation in induced sputum
In contrast to peripheral blood, flow cytometric analysis of the
killer cells from induced sputum showed no effect of current
smoking per se (Figure 5). Specifically, a significantly higher
proportion of CD8+ T-lymphocytes from both current smokers
with COPD (88.2%, 70.6–97.1; p,0.001) and ex-smokers with
COPD (69.3%, 64.3–79.7; p,0.005) were activated ex vivo
compared to healthy non-smokers (26.1%, 16.2–28.2). Further-
more, a significantly higher proportion of CD8+ T-lymphocytes
from current smokers with COPD (88.2%, 70.6–97.1; p,0.05)
were activated compared to healthy smokers (46.2%, 27.0–57.3)
(Figure 5A).
The proportion of activated NKT-like cells ex vivo was
significantly higher from both current smokers with COPD
(87.5%, 80.0–93.3; p,0.001) and ex-smokers with COPD
(69.8%, 62.0–78.7; p,0.005) compared to healthy non-smokers
(15.0%, 7.5–21.0). In addition, a significantly higher proportion of
NKT-like (CD56+CD3+) cells from current smokers with COPD
(87.5%, 80.0–93.3; p,0.005,) were activated compared to healthy
smokers (34.8%, 19.4–47.7) (Figure 5B).
The proportion of activated NK cells ex vivo was significantly
higher from both current smokers with COPD (87.5%, 75.1–96.9;
p,0.001) and ex-smokers with COPD (66.7%, 61.9–78.7;
p,0.05) compared to healthy non-smokers (32.1%, 23.5–41.6).
In addition, a significantly higher proportion of NK
(CD56+CD32) cells from current smokers with COPD (87.5%,
75.1–96.9; p,0.005) were activated compared to healthy smokers
(41.1%, 25.6–52.5) (Figure 5C).
There was no difference in cell viability (% total) in induced
sputum between current and ex-smokers with COPD, healthy
smokers and healthy non-smokers (median, range): 83% (75–92),
84% (79–94), 82% (72–93) and 86% (75–94), respectively. In all
samples, more than 90% of the cells were non-squamous.
Discussion
Here we report, for the first time, that current smoking per se is
associated with a significantly higher proportion of peripheral
blood cytotoxic cells that are activated ex vivo and this is positively
correlated with the number of cigarettes currently smoked per day.
Furthermore, we show that, in induced sputum, it is the presence
of COPD, rather than current smoking, that relates to cytotoxic
cell activation.
We have previously demonstrated the potential involvement of
the three main classes of human killer cells, namely, CD8+ T-
lymphocytes, NKT-like cells and NK cells in COPD (7, 10, 11).
These killer cells play key roles in inflammatory responses and
activation of these cells can cause the production of inflammatory
cytokines and chemokines, such as TNF-a and IL-8, that can
induce pathological features of COPD and lung tissue damage
[32]. Therefore, we hypothesised that killer cells are more active in
COPD patients. Here we examined the ex vivo activation
phenotype of these cells both in the peripheral blood and induced
Figure 4. Expression of KIR by peripheral blood cells in four groups. (i) Representative dot plots of KIR expression: (Panel A) healthy non-
smokers; (Panel B) healthy smokers; (Panel C) current smokers with COPD and (Panel D) ex-smokers with COPD. (ii) CD8+ T lymphocytes (Panel A),
NKT-like (CD56+CD3+) cells (Panel B) and NK (CD56+CD32) cells (Panel C). A significantly lower proportion of CD8+ T lymphocytes, NKT-like
(CD56+CD3+) cells and NK (CD56+CD32) cells from healthy smokers (HS, open circles) and cuS-COPD (solid circles) expressed KIR on the cell surface
compared to healthy non-smokers (HNS). ***: p,0.001. HNS (n = 8); HS (n = 8); cuS-COPD participants (n = 9) and exS-COPD (n= 7).
doi:10.1371/journal.pone.0058556.g004
Killer Cell Activation States Ex Vivo in COPD
PLOS ONE | www.plosone.org 7 March 2013 | Volume 8 | Issue 3 | e58556
sputum. In peripheral blood, current smokers with or without
COPD have the highest proportion of activated CD8+ T-
lymphocytes, NKT-like cells and NK cells compared with healthy
non-smokers and ex-smokers with COPD. This suggests that
smoking per se affects systemic killer cell activation. We thus
examined the correlation between current smoking profiles and
cell activation levels. Here we show that CD8+ T-lymphocyte and
NK cell activation is positively correlated with the number of
cigarettes currently smoked. No correlations between cell activa-
tion and lung function (FEV1 percentage of predicted) were found
(data not shown). These data suggest that, in peripheral blood, cell
activation levels are more related to current smoking habit rather
than disease.
Similar studies have shown that ex-smokers with COPD have
significantly fewer CD8+CD25+ T-lymphocytes in BAL fluid
compared to current smokers with COPD [28]. Furthermore,
examining systemic CD4+ T-lymphocytes, also thought to be
important in the pathogenesis of COPD, have shown a correlation
between CD69 expression and lung function in COPD [26].
Sputum T-lymphocytes have been shown to express higher levels
of CD103 and CD69 than blood lymphocytes, suggesting higher
numbers of activated intra-epithelial phenotype T-lymphocytes in
the lung [27].
To investigate a possible mechanism for differences in activation
states observed in peripheral blood, we compared expression of the
KIR CD158e1. Interestingly, in our study, the expression levels of
the inhibitory KIR CD158e1 were lower in peripheral blood of
current smokers with or without COPD compared to healthy non-
smokers, which is the opposite to the activation levels of these killer
cells. This suggests that the down regulation of the inhibitory KIRs
may be associated with cell activation. There is evidence that
expression of KIR may be a feature of differentiation towards a
memory phenotype [33]. However, these cells possess not only
inhibitory receptors but also activating receptors and killing ability
is determined by a balance of signals from both types of receptors.
We also compared the expression levels of one activating receptor
NKG2D. Unlike CD158e1 KIR expression, no significant
differences in NKG2D expression were measured between the
four groups. They were all highly expressed by those activated cells
(data not shown). This further supports the proposal of increased
peripheral blood killer cell activity in smokers due to the increased
ratio of activating to inhibitory receptors.
In contrast to our findings in peripheral blood, in induced
sputum the proportion of activated cells is more related to disease
state than current smoking, with both current and ex-smokers with
COPD having significantly higher rates of activation than healthy
non-smokers and healthy smokers. One hypothesis for these
differences is that, in COPD, activated killer cells may have
migrated to the lung from peripheral blood. Due to size differences
between these compartments it is not surprising that this increased
migration does not significantly affect the proportion of cells within
the blood. A previous study examining the effect of smoking
cessation has shown in BAL fluid that CD8+ T-lymphocytes from
both smokers with normal lung function and COPD participants
expressed high levels of CD69 and CD25 activation markers [28].
This difference may represent the use of lavage rather than
induced sputum used in our study.
The present study has some limitations that deserve comment.
Firstly, we used CD69 and CD25 as activation markers. Although
other markers exist, these are generally accepted as representing
cell activation [34,35]. Secondly, CD25 is commonly used as a
marker for T regulatory cells but these cells will express high levels
of CD25 and for the present study only moderate levels were
detected [36]. Thirdly, there are many kinds of inhibitory and
Figure 5. Activation of killer cells in induced sputum of four
groups. CD8+ T-lymphocytes (Panel A), NKT-like (CD56+CD3+) cells
(Panel B) and NK (CD56+CD32) cells (Panel C). A significant increase in
level of activation ex vivo of CD8+ T lymphocytes, NKT-like (CD56+CD3+)
cells and NK (CD56+CD32) cells from COPD patients with or without
smoking history compared with healthy non-smokers (HNS). *: p,0.05,
**: p,0.01, ***: p,0.001. HNS (n = 5), HS (n = 10), cuS-COPD participants
(n = 5) and exS-COPD (n = 6).
doi:10.1371/journal.pone.0058556.g005
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activating receptors expressed on these cells but, due to limited cell
numbers, we analysed two representative receptors that give an
indication of the killing function of these cells. Fourthly, it should
be noted that the majority of participants with COPD were taking
inhaled corticosteroids. However, the two participants who were
not on inhaled corticosteroids in this group showed the same
results in terms of activation and KIR expression as those on
inhaled corticosteroids. Finally, we used induced sputum to
examine the activation state of cells. This does not reflect changes
in the lower airway or within bronchial tissue but it is a convenient
and non-invasive research tool [37,38]. It would be important to
follow up our findings by investigating BAL and bronchial biopsies
in these groups of patients.
Conclusion
In summary, we have shown, for the first time, a differential
effect in systemic activation and lung activation of killer cells in
COPD. Importantly, we have shown that systemic activation is in
response to smoking per se whereas lung activation is due
specifically to COPD, irrespective of current smoking status.
Taken together, these findings indicate that activation of killer cells
within the airways of COPD participants may play a role in the
pathogenesis of COPD.
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